Biotech Co.* |
Pharma Co. |
Product |
Terms/Details (Date) |
| | |||
Agenix Inc. |
Diosynth Biotechnology (unit of NV Organon) |
Diosynth will manufacture ThromboView for Phase III trials and commercial sale |
The product uses radiolabeled antibodies to locate blood clots in the body; terms of the deal were not disclosed (8/10) |
Allos |
Hovione (Portugal) |
Deal under which Hovione will manufacture Efaproxyn bulk drug substance |
The Phase III product is designed to sensitize hypoxic areas of tumors during radiation; the deal covers both pre- and post- commercialization needs (6/16) |
AlphaVax Inc.* |
Greer Laboratories |
AlphaVax assumed direct responsibility for vaccine manufacturing under a new lease agreement with Greer |
AlphaVax will use Greer's vaccine production facility, and will employ several Greer staff who are involved in making AlphaVax vaccines; terms were not disclosed (6/23) |
Ark |
BL&H Co. Ltd. (South Korea) |
BL&H got rights in South Korea to the wound-healing product Kerraboot |
Ark would get a double-digit royalty on sales in the covered territory (6/14) |
Avantogen |
Dr. Reddy's Laboratories (India) |
Deal for the production of Avantogen's GPI-100 adjuvant |
Dr. Reddy's will manufacture the product under undisclosed terms (6/23) |
BioDiscovery |
Tecan Schweiz AG (Switzerland) |
Collaboration to develop a data-management solution for interpreting microarray data |
They will integrate technologies in the deal, terms of which were not disclosed (6/29) |
Co.don AG* |
Bioengi Ltd. (Italy) |
Bioengi will market Co.don's products for treating osteo-arthritic knee joints and degenerated intervertebral discs |
The products are co.don chondrotrans-plant, co.don chondrosphere and co.don chondrotranspant DISC; terms of the deal were not disclosed (6/8) |
Cortex |
Bouty SpA (Italy) |
Bouty got rights to market Cortex's MagaZorb Nucleic Acid Isolation Kits and associated reagents in Italy |
The exclusive distribution deal includes Bouty's biotechnology division, Techno-genetics Srl; terms of the deal were not disclosed (6/14) |
DOR |
Dowpharma |
Dow will provide process development services for DOR's oral botulinum vaccine, |
Dow will use its Pseudomonas-based Pfenex Expression Technology in the effort; terms of the deal were not disclosed (7/26) |
GeneGo Inc.* |
Rosetta Biosoftware (unit of Merck & Co. Inc.) |
Deal to establish interoperability between Rosetta's Resolver system and GeneGo's MetaCore system |
Researchers will be able to exchange data between the systems for analyzing gene expression data and for pathway analysis; terms were not disclosed (7/18) |
Gene Logic |
GE Healthcare |
Deal under which GE will distribute Gene Logic's Sciantis System worldwide |
The product is an an online gene expression analysis system; terms of the deal were not disclosed (7/19) |
Generex |
MedGen Corp. (Lebanon) |
MedGen got marketing rights to the diabetes product Oral-lyn in Lebanon |
MedGen made an up-front license payment and is obligated to certain minimum purchases of the product from Generex (6/16) |
Iconix |
Rosetta Biosoftware (unit of Merck & Co. Inc.) |
Deal to establish inter-operability between their systems |
The deal involves Rosetta's Resolver system and Iconix's DrugMatrix Informatics system; terms were not disclosed (6/20) |
Immuno- |
Cambridge Laboratories Ltd. (UK) |
CLL got marketing rights to Junovan (Mepact or L-MTP-PE), a Phase III cancer product, in the UK and Ireland |
IDM gets an up-front license fee and is entitled to milestone payments, as well as royalties on any resulting sales (6/21) |
Iomai Corp.* |
The Dow Chemical Co. |
Iomai will use the Pfenex Expression Technology from Dowpharma to produce heat labile enterotoxin |
Iomai will use the technology to produce a component of its platform for the delivery of vaccines to the skin; terms were not disclosed (6/24) |
Lantibio Inc.* |
Apotex |
Apotex will supply and help in the development of Lantibio's Moli1901 product |
The product is being developed for dry-eye syndrome and cystic fibrosis; Apotex is entitled to royalty payments (8/15) |
Microbix |
Undisclosed vaccine producer |
They extended by 90 days a deal to evaluate Microbix's technology to boost the production yield of flu vaccine |
The initial evaluation period was to expire June 30; terms of the deal were not disclosed (6/24) |
Morphotek |
Baxter Healthcare Corp. |
They expanded existing deal to include manufacturing of Morphotek's Phase I cancer antibody MORAb-003 |
Baxter already was manufacturing MORAb- 009 and MORAb- 04; terms of the deal were not disclosed (6/30) |
Neurobiological |
Nordmark Arzneimittel GmbH & Co KG (Germany) and Baxter Pharmaceutical Solutions LLC |
Deal for the manufacturing and packaging of NTI's Viprinex (ancrod) for Phase III trials in acute ischemic stroke |
Nordmark will manufacture the biological active ingredient, and Bayer will fill and package the product; terms of the deal were not disclosed (6/27) |
Osiris |
JCR Pharmaceuticals Co. Ltd. (Japan) |
JCR got rights in Japan to sell stem cells for use in drug screening and evaluation |
The deal is an expansion of a license agreement under which JCR got rights to a stem cell drug for treating grafts-host disease (8/4) |
Physiomics plc |
Bayer |
Physiomics will distribute Bayer's PK-Sim pharmaco-kinetic modeling products and services |
Terms of the exclusive, renewable five-year deal were not disclosed (6/23) |
QBI Life |
Takara Bio Inc. (Japan) |
Takara will distribute QBI's tools for membrane proteins in Japan, China and Korea |
Terms of the deal were not disclosed (7/18) |
VaxGen Inc. |
Bristol-Myers Squibb Co. |
VaxGen's joint venture Celltrion will manufacture biologic products being developed by BMS |
Celltrion, in South Korea, was established by Vaxgen and three South Korean partners; terms of the deal were not disclosed (6/21) |
Verus |
Hollister-Stier Laboratories LLC |
Verus acquired exclusive, worldwide rights to the approved product Twinject |
Twinject is an epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis); it also got rights to other technology and development programs (7/6) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market; ASX = Australian Stock Exchange; AMEX = American Stock Exchange; LSE = London Stock Exchange; PK = Pink Sheets; TSE = Toronto Stock Exchange. | |||
